We claim:

1. An mRNA comprising an open reading frame encoding an RNA-guided DNA-binding agent, wherein the open reading frame has:

a) an adenine content ranging from its minimum adenine content to 150% of the minimum adenine content; or

b) an adenine dinucleotide content ranging from its minimum adenine dinucleotide content to 150% of the minimum adenine dinucleotide content.

2. An mRNA comprising a sequence with at least 90% identity to any one of SEQ ID NO: 111, 113-119, 128, 146, 148-154, and 163, wherein the mRNA comprises an open reading frame encoding an RNA-guided DNA-binding agent.

3. An mRNA comprising an open reading frame encoding an RNA-guided DNA-binding agent, wherein the open reading frame has at least 90% identity to any one of SEQ ID NO: 111, 113-119, 128, 146, 148-154, and 163 over at least the first 30, 50, 70, 100, 150, 200, 250, or 300 nucleotides of any one of SEQ ID NO: 111, 113-119, 128, 146, 148-154, and 163.

4. The mRNA of any one of the preceding claims, wherein the open reading frame consists of a set of codons of which at least 75% of the codons are (i) chosen from the set of codons listed in Table 2 or (ii) chosen from the set of codons listed in the table below:

Amino Acid	Low A
Gly	GGC
Glu	GAG
Asp	GAC
Val	GTG
Ala	GCC
Arg	CGG
Ser	TCC
Lys	AAG
Asn	AAC
Met	ATG
Ile	ATC
Thr	ACC

Trp	TGG
Cys	TGC
Tyr	TAC
Leu	CTG
Phe	TTC
Gln	CAG
His	CAC

.

5. An mRNA encoding an RNA-guided DNA-binding agent comprising an open reading frame encoding an RNA-guided DNA-binding agent, wherein the open reading frame consists of a set of codons of which at least 75% of the codons are (i) chosen from the set of codons listed in Table 2 or (ii) chosen from the set of codons listed in the table below:

Amino Acid	Low A
Gly	GGC
Glu	GAG
Asp	GAC
Val	GTG
Ala	GCC
Arg	CGG
Ser	TCC
Lys	AAG
Asn	AAC
Met	ATG
Ile	ATC
Thr	ACC
Trp	TGG

Cys	TGC
Tyr	TAC
Leu	CTG
Phe	TTC
Gln	CAG
His	CAC

.

6. The mRNA of any one of the preceding claims, wherein the open reading frame has an adenine content ranging from its minimum adenine content to 101%, 102%, 103%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, or 150% of the minimum adenine content.

7. The mRNA of any one of the preceding claims, wherein the open reading frame has an adenine dinucleotide content ranging from its minimum adenine dinucleotide content to 101%, 102%, 103%, 105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, or 150% of the minimum adenine dinucleotide content.

8. The mRNA of any one of the preceding claims, wherein the open reading frame has codons that increase translation of the mRNA in a mammal.

9. The mRNA of claim 8, wherein the open reading frame has codons that increase translation of the mRNA in a specific organ of a mammal.

10. The mRNA of claim 9, wherein the organ is liver.

11. The mRNA of any one of claims 8 to 10, wherein the mammal is a human.

12. An mRNA comprising an open reading frame encoding a Cas9 nuclease, wherein the Cas9 nuclease comprises the amino acid sequence of SEQ ID NO: 13, wherein each of the codons of the amino acid sequence of SEQ ID NO: 13 is a low A codon from the table below, and wherein each thymidine in the mRNA is replaced with a modified or unmodified uridine:

Amino Acid	Low A
Gly	GGC
Glu	GAG
Asp	GAC

Val	GTG
Ala	GCC
Arg	CGG
Ser	TCC
Lys	AAG
Asn	AAC
Met	ATG
Ile	ATC
Thr	ACC
Trp	TGG
Cys	TGC
Tyr	TAC
Leu	CTG
Phe	TTC
Gln	CAG
His	CAC
Pro	CCC

.

13. The mRNA of any one of the preceding claims, which comprises a 5' UTR with at least 90% identity to any one of SEQ ID NOs: 32, 34, 36, 38, 41, or 75-77.

14. The mRNA of any one of the preceding claims, which comprises a 3' UTR with at least 90% identity to any one of SEQ ID NOs: 33, 35, 37, 39, or 40.

15. The mRNA of claim 13 or 14, wherein the mRNA comprises a 5' UTR and a 3' UTR from the same source.

16. The mRNA of any one of the preceding claims, wherein the encoded RNA-guided DNA-binding agent comprises a nuclear localization signal (NLS).

17. An mRNA comprising an open reading frame encoding an RNA-guided DNA-binding agent, comprising the SEQ ID NO: 177.

18. The mRNA of any one of the preceding claims, wherein the mRNA further comprises a 5' cap.

19. The mRNA of claim 18, wherein the 5' cap is selected from Cap0, Cap1, and Cap2.

20. The mRNA of any of the preceding claims, wherein 10%-25%, 15-25%, 25-35%, 35-45%, 45-55%, 55-65%, 65-75%, 75-85%, 85-95%, or 90-100% of the uridines of the mRNA are modified uridines.

21. The mRNA of claim 20, wherein the modified uridines comprise N1-methyl-pseudouridines, pseudouridines, 5-methoxyuridines, or 5-iodouridines.

22. The mRNA of claim 21, wherein at least 90% of the uridines of the mRNA are N1-methyl-pseudouridines.

23. The mRNA of claim 21, wherein 100% uridines of the mRNA are N1-methyl-pseudouridines.

24. An expression construct comprising a promoter operably linked to a sequence encoding an mRNA according to any one of the preceding claims.

25. A plasmid comprising the expression construct of claim 24.

26. A host cell comprising the expression construct of claim 24 or the plasmid of claim 25.

27. A method of preparing an mRNA comprising contacting the expression construct of claim 24 or the plasmid of claim 25 with an RNA polymerase under conditions permissive for transcription of the mRNA.

28. The method of claim 27, wherein the contacting step is performed in vitro.

29. A composition comprising an mRNA according to any one of claims 1-23 and at least one guide RNA.

30. A lipid nanoparticle comprising an mRNA according to any one of claims 1-23.

31. A pharmaceutical composition comprising an mRNA according to any one of claims 1-23 and a pharmaceutically acceptable carrier.

32. The lipid nanoparticle of claim 30 or the pharmaceutical composition of claim 30, further comprising at least one guide RNA.

33. The pharmaceutical composition of claim 31 or 32 or the lipid nanoparticle of claim 30 or 32, wherein the at least one guide RNA targets TTR.

34. A method of genome editing or modifying a target gene comprising contacting a cell with the mRNA according to any one of claims 1-23, the expression construct of claim 22, the pharmaceutical composition of any one of claims 31-33, or the lipid nanoparticle according to any one of claims 30, 32, and 33.

35. Use of the mRNA according to any one of claims 1-23, the expression construct of claim 22, the pharmaceutical composition of any one of claims 31-33, or the lipid nanoparticle according to any one of claims 30, 32, and 33 for genome editing or modifying a target gene.

36. Use of the mRNA according to any one of claims 1-23, the expression construct of claim 22, the pharmaceutical composition of any one of claims 31-33, or the lipid nanoparticle according to any one of claims 30, 32, and 33 for the manufacture of a medicament for genome editing or modifying a target gene.

37. The method of claim 34 or the use of claim 35 or 36, wherein the genome editing or modification of the target gene occurs in a liver cell.

38. The method or use of claim 37, wherein the liver cell is a hepatocyte.

39. The method of any one of claims 34, 37 and 38 or the use of any one of claims 35-38, wherein the genome editing or modification of the target gene is in vivo.

40. The method of any one of claims 34, 37 and 38 or the use of any one of claims 35-38, wherein the genome editing or modification of the target gene is in an isolated or cultured cell.